GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » Cash-to-Debt

NXTC (NextCure) Cash-to-Debt : 11.54 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is NextCure Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NextCure's cash to debt ratio for the quarter that ended in Dec. 2024 was 11.54.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, NextCure could pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.

The historical rank and industry rank for NextCure's Cash-to-Debt or its related term are showing as below:

NXTC' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.74   Med: 44.69   Max: No Debt
Current: 11.54

During the past 8 years, NextCure's highest Cash to Debt Ratio was No Debt. The lowest was 8.74. And the median was 44.69.

NXTC's Cash-to-Debt is ranked better than
56.01% of 1482 companies
in the Biotechnology industry
Industry Median: 7.525 vs NXTC: 11.54

NextCure Cash-to-Debt Historical Data

The historical data trend for NextCure's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NextCure Cash-to-Debt Chart

NextCure Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial 81.62 No Debt 22.45 16.40 11.54

NextCure Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.40 16.63 15.46 13.98 11.54

Competitive Comparison of NextCure's Cash-to-Debt

For the Biotechnology subindustry, NextCure's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCure's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCure's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NextCure's Cash-to-Debt falls into.


;
;

NextCure Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NextCure's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

NextCure's Cash to Debt Ratio for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NextCure  (NAS:NXTC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


NextCure Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NextCure's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


NextCure Business Description

Traded in Other Exchanges
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Executives
Anne Elizabeth Borgman director 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw officer: Sr VP, Legal Affairs 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu officer: Sr VP, Dev. & Mfg. 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint officer: Chief Medical Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer officer: Chief Operating Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann officer: Chief Scientific Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn officer: Chief Financial Officer C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu officer: SVP, Research C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman director, officer: President & CEO 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025